...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: AACR

NBB - It is long past running out of money, The Jan.31, MD&A stated that they had $100,000 cash and a monthly burn rate of $800,000. There doesn't seem to be any panic so you can read what you want into that. Is there something in the wind?

"As at January 31, 2019, we had $0.1 million of cash and $2.4 million of trade and other payables and we were committed to pay various amounts as described below under “Contractual Obligations”. We believe our cash as at January 31, 2019, together with expected payments from Pfizer Inc., is not sufficient to fund our contractual commitments over at least the next year and is not sufficient to fund our planned business operations over the next year. We will continue to pursue alternatives to raise additional capital including issuing additional equity and/or debt and/or from other sources such as partnering and/or licensing; however, there is no assurance that these initiatives will be successful. These conditions result in a material uncertainty which may cast significant doubt on our ability to continue as a going concern."

Share
New Message
Please login to post a reply